Navigation Links
Experimental Vaccine Shows Promise for Lung Cancer: Study
Date:10/24/2011

MONDAY, Oct. 24 (HealthDay News) -- New research suggests that physicians may be able to strengthen the power of chemotherapy in patients with the most common form of lung cancer by adding a cancer vaccine to the treatment.

The combined treatment for non-small cell lung cancer was tested in a phase 2 study and still has to go through more research, as experimental drugs go through three phases of study. Although the rate of serious side effects was somewhat higher in those who received both treatments compared to chemotherapy alone, this new approach seems feasible, the study authors said.

Commenting on the study, Srikumar Chellappan, chair of the department of tumor biology and scientific director of the National Functional Genomics Center at H. Lee Moffitt Cancer Center and Research Institute in Tampa, Fla., said that the research is promising and the treatment could become a new strategy.

Chellappan, who was not involved with the study but is familiar with the findings, noted there are caveats. "It should be pointed out that the increases in overall survival and progression-free survival are not dramatic, but any increase is very welcome, considering that the patients are in an advanced stage of cancer."

Patients with advanced non-small cell lung cancer have very low survival rates because of the spread of cancer to various organs in the body, such as the brain, Chellappan noted.

Currently, patients with advanced disease are treated with chemotherapy. In the study, published online Oct. 22 in The Lancet Oncology, Elisabeth Quoix from the University of Strasbourg in France and colleagues assigned 148 patients in the advanced stages of non-small cell lung cancer to either receive the experimental cancer vaccine called TG4014 in combination with chemotherapy or receive chemotherapy alone.

After six months, the cancer in 43 percent of those given the combination treatment hadn't progressed compared to 35 percent of those who took chemotherapy alone. The combo treatment was especially beneficial in a subgroup of patients who had a normal number of a type of immune response cells called "natural killer cells" upon entering the study, the researchers noted in a journal news release.

The rate of serious side effects was 52 percent in those given the combo treatment and 47 percent in those who received chemotherapy alone.

Non-small cell lung cancer is the number one cause of cancer death worldwide, and nearly half of these patients already have advanced disease by the time they are diagnosed, the authors noted in the news release.

More information

For more about lung cancer, visit the U.S. National Library of Medicine.

-- Randy Dotinga

SOURCES: Srikumar Chellappan, Ph.D., chair, department of tumor biology and scientific director, National Functional Genomics Center, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Fla.; Oct. 22, 2011, The Lancet Oncology, online


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Experimental Drug Offers Hope for Cystic Fibrosis Patients
2. Experimental Vaccine Shields Monkeys Against Ebola
3. Experimental targeted therapy shows early promise against medulloblastomas
4. Experimental nonsteroidal treatment of asthma shows promise
5. Experimental obesity drug avoids brain effects that troubled predecessors
6. Experimental treatments for cocaine addiction may prevent relapse
7. Experimental TB Test Called Fast and Accurate
8. Experimental Drug Shows Promise for Bone Marrow Disorder
9. Experimental Leukemia Drug Proves a Slam Dunk
10. Experimental Test May Spot Prostate Cancer Earlier, More Accurately
11. Experimental Drug Aids Kids With Nervous System Tumor
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Experimental Vaccine Shows Promise for Lung Cancer: Study 
(Date:12/2/2016)... ... December 02, 2016 , ... U.S. Surgeon General, Dr. Vivek Murthy, ... Murthy explains how he was inspired to practice medicine at an early age by ... about more than making diagnoses and prescribing medicine,” he states. “It is about building ...
(Date:12/2/2016)... York, NY (PRWEB) , ... December 02, 2016 , ... ... high school and while 84 percent of parents report speaking with their child about ... pornography and sexually transmitted diseases. , Mediaplanet is proud to announce the launch of ...
(Date:12/2/2016)... ... December 02, 2016 , ... Universal Medical Systems, Inc. ... the first company to offer robotic imaging to veterinary medicine is sponsoring the ... 941 for the American Association of Equine Practitioners 62nd Annual Convention from December ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... "Pro3rd Accents ... FCPX editors to create versatile lower third titles with just a few clicks of ... Accents Volume 2 includes 30 lower third animations. Choose from various styles with accented ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... Scientist & Author of Type 2 Diabetes: The Owner’s Manual, http://realtimepressrelease.com/press-releases-tagged-with/daryl-wein ... Kleyne Hour Power of Water, Global Climate Change and Your Health radio program ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... 2016 Lianluo Smart Limited (Nasdaq: ... which develops, markets and sells medical devices and ... and international markets, recently attended the ... New Progress Forum, co-hosted by the Institute of ... , Guangdong Provincial People,s Hospital and Cardiology Department ...
(Date:12/2/2016)... 1, 2016 The concept of rare diseases and ... to this sector has been taking shape in ... political aspects and initiatives related to orphan medicinal products have ... level of member states individually. Many member states in the ... space of orphan medicinal products, the result of which took ...
(Date:12/2/2016)... Allergan plc (NYSE: AGN ), a ... previously announced Accelerated Share Repurchase (ASR) Program. Logo - ... ... previously announced, the Company entered into a variable tenor ASR ... repurchase $10 billion of its ordinary shares. Approximately 40.5 million ...
Breaking Medicine Technology: